IGF-1 LR3 (1mg/100mcg)

What is IGF-1 LR3 (Receptor Grade)?

IGF-1 LR3 is the catalog name for a long-R3 analog of insulin-like growth factor 1. The named research construct is commonly described as an 83-amino-acid IGF-1 analog with an N-terminal extension and an arginine substitution at position 3. This catalog lists 100mcg and 1mg research vials.

Listed vial contents: 1mg / 100mcg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

Which identity should I verify?

Confirm the intended 83-amino-acid long-R3 IGF-1 construct with a supplier specification, then match the observed intact mass and chromatogram to the same lot. The product label and vial amount identify the marketed item, not its analytical identity.

What mechanisms are being studied?

Researchers use long-R3 IGF-1 analogs to study IGF-receptor signaling under conditions where interactions with insulin-like-growth-factor-binding proteins differ from native IGF-1. Results depend on the exact construct, model and assay, so the catalog name cannot substitute for sequence and mass confirmation.

What are the research questions?

• IGF-receptor signaling in defined cell systems
• How reduced binding-protein interactions alter experimental responses
• Comparisons with native IGF-1 and Des(1-3) IGF-1

What does the published work describe?

Published animal work with long-R3 IGF-I reported organ-growth and circulating IGF-system measurements in guinea pigs. That study concerns its named experimental material; it does not establish a universal half-life, potency multiplier or outcome for this catalog vial.

Experimental models in the cited papers

• Guinea pig: long-R3 IGF-I infusion and IGF-system measurements

What could future research explore?

Direct analytical comparison of the supplied material with a stated long-R3 reference standard could establish whether the intended sequence and intact mass are present. Functional studies could then compare it with native IGF-1 and Des(1-3) IGF-1 under matched conditions.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

The cited study does not verify this vial's sequence, intact mass, quantity, purity, sterility, effectiveness or safety. No clinical benefit is established. Fixed pharmacokinetic or potency claims are not presented because they are not supported for this inventory.

Study references

1. Tomas FM, et al. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995. PMID 7561636

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. Generated sample reports illustrate the reporting flow and are not evidence of testing, purity or accreditation.